This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
25th August 2026

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake
	(Security Code: 190A TSE Growth Market)
Contact:	Chief Financial Officer Masaru Okatani
MAIL :	info@chordiatherapeutics.com

Announcement of Orphan Drug Designation in Japan for rogocekib for Relapsed or Refractory AML

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) hereby announces that, as disclosed in its press release dated July 28, 2026, entitled "Announcement Regarding the Review Status of Orphan Drug Designation for Rogocekib, a CLK Inhibitor," rogocekib, Chordia’s lead pipeline asset and a CLK inhibitor, has been granted Orphan Drug Designation by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of relapsed or refractory acute myeloid leukemia (AML).

The Orphan Drug Designation system is intended to support research and development and promote the practical use of drugs for diseases with a small patient population and high unmet medical need.

This designation enables rogocekib to be eligible for various support measures, including subsidies for research and development expenses, and facilitates continued development through close collaboration with regulatory authorities.

Chordia believes that this designation will further support the development of rogocekib and remains committed to advancing its development with the goal of delivering this treatment to patients in need as quickly as possible.
This designation is not expected to have any material impact on the Company's financial results.

About CLK inhibitor rogocekib (development code: CTX-712)

rogocekib is a first-in-class, selective, orally available small molecule inhibitor targeting CDC2-like kinase (CLK), a key regulator of RNA splicing involved in cell proliferation. It has received Orphan Drug Designation (ODD) from the FDA for the treatment of AML and is currently undergoing a Phase 1/2 clinical trial in the United States.

About Chordia Therapeutics

Chordia Therapeutics is a research and development-stage biopharmaceutical company specializing in oncology with clinical-stage assets, headquartered in

Fujisawa City, Kanagawa Prefecture. Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including ocipumaltib (MALT1 inhibitor CTX-177) , CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website https://www.chordiatherapeutics.com/en/.